Should patients with CKD stage 5D and biochemical evidence of secondary hyperparathyroidism be prescribed calcimimetic therapy? An ERA-EDTA position statement.
This paper reflects the position of the CKD-MBD workgroup, an official working group of ERA-EDTA and of the ERBP advisory board, the official guideline-producing body of ERA-EDTA, on the topic of the use of calcimimetics in patients with CKD stage 5D, as based on two recent meta-analysis.
Renal and Transplantation Department, Guy's and St Thomas' Hospitals, London, UK.
David
D
Goldsmith
Nephrology Department, Gr. T. Popa University of Medicine and Pharmacy, Iasi, Romania.
Adrian
A
Covic
Department of Nephrology, VU University Medical Center, Amsterdam, The Netherlands Institute for Cardiovascular Research VU (ICaR-VU), VU University Medical Center, Amsterdam, The Netherlands.
Marc
M
Vervloet
Department of Health Sciences, University of Milan Renal Division S. Paolo Hospital, Milan, Italy.
Mario
M
Cozzolino
Nephrology Department, Gr. T. Popa University of Medicine and Pharmacy, Iasi, Romania Methods Support Team of European Renal Best Practice, Ghent University Hospital, Ghent, Belgium.
Ionut
I
Nistor
D000069449:Cinacalcet; D002986:Clinical Trials as Topic; D005060:Europe; D006801:Humans; D006962:Hyperparathyroidism, Secondary / Q000188:drug therapy*; D015201:Meta-Analysis as Topic; D009281:Naphthalenes / Q000008:administration & dosage; D009398:Nephrology / Q000592:standards*; D010710:Phosphates / Q000737:chemistry; D051436:Renal Insufficiency, Chronic / Q000150:complications* / Q000188:drug therapy*; D012955:Societies, Medical; D013261:Sterols / Q000008:administration & dosage; D016896:Treatment Outcome; D014807:Vitamin D / Q000008:administration & dosage
D009281:Naphthalenes; D010710:Phosphates; D013261:Sterols; D014807:Vitamin D; D000069449:Cinacalcet
calcimimetics